Mark J. Foley - 15 Mar 2024 Form 4 Insider Report for Revance Therapeutics, Inc.

Signature
/s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 Mar 2024
Net transactions value
-$108,928
Form type
4
Filing time
19 Mar 2024, 18:43:19 UTC
Previous filing
08 Mar 2024
Next filing
03 Jun 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Tax liability $17,533 -3,305 -0.33% $5.30 1,012,163 15 Mar 2024 Direct F1
transaction RVNC Common Stock Tax liability $91,395 -17,228 -1.7% $5.30 994,935 15 Mar 2024 Direct F2
holding RVNC Common Stock 110,913 15 Mar 2024 See footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock award (the "RSA") for 13,572 shares. The RSA vested in three equal annual installments from March 15, 2021.
F2 Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the performance-based restricted stock units ("PSUs") granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals.
F3 These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.